LetterOne LetterOne LetterOne

Annalisa Jenkins

L1 Health Advisory Board

L1 Board

Annalisa Jenkins MBBS FRCP is a biopharma thought leader with over 25 years' industry experience. Dr Jenkins has extensive recent experience in building and financing biotech companies, pursuing cures for the most challenging rare diseases to addressing important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally.  In addition, she is an advocate for diversity and inclusion, particularly for women in science.

Dr Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior leadership roles have included the Head of Global Research and Development and Executive Vice President Global Development and Medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as Senior Vice President and Head of Global Medical Affairs.

Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander.

Dr Jenkins is a board member of several growing companies, including Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, Phaim Pharma, Conduit Connect, Affimed, Genomics England, Blue Advent Ltd, Perspectum Ltd, Cyte Limited, Ori Biotech, Arctech Innovation and Cocoon Biotech Inc (Non-Executive Chair). She is also a trustee for The King's Fund, medical trustee for the British Heart Foundation and a committee member of the Science Board to the US Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues, an advisory board member at FasterCures, a centre of The Milken Institute and Chair of The Court The London School of Hygiene and Tropical Medicine.